Assessment and Management of Neuropsychiatric Symptoms in Parkinson’s Disease

  title={Assessment and Management of Neuropsychiatric Symptoms in Parkinson’s Disease},
  author={Christoph Mueller and Anto P. Rajkumar and Yi Min Wan and Latha Velayudhan and Dominic H. Ffytche and Kallol Ray Chaudhuri and Dag Aarsland},
  journal={CNS Drugs},
Neuropsychiatric symptoms are highly prevalent in Parkinson’s disease and associated with decreased quality of life and adverse health outcomes. In this review, the assessment and management of common neuropsychiatric symptoms are discussed: depression, anxiety, psychosis, cognitive impairment, dementia and apathy. Validated assessment scales are now available for the majority of symptoms. Balancing dopaminergic therapy plays an important role in their management as increasing doses of… 
Mood Disorders and Anxiety in Parkinson’s Disease: Current Concepts
This review explores both the pharmacologic and non-pharmacologic treatment modalities for various mood disorders in comorbid Parkinson’s disease with a brief discussion of the future outlook of the field given the current state of the literature.
Current treatment of behavioral and cognitive symptoms of Parkinson's disease.
  • I. Rektorová
  • Psychology, Medicine
    Parkinsonism & related disorders
  • 2019
Psychosis in Parkinson's disease in a Southeast Asian cohort: prevalence and clinical correlates.
Investigation of the prevalence of PD-associated psychosis in the local setting in Singapore found that the presence of psychosis significantly predicted greater cognitive decline and disease severity, possibly serving as an indicator of more rapid Cognitive decline and progression of PD severity.
Psychosis Management in Lewy Body Dementia: A Comprehensive Clinical Approach
Goal of care and functional assessment are a crucial part of the optimized care plan, given overall guarded prognosis, in the context of numerous complications observed in this population of dementia patients.
Pharmacologic Approaches for the Management of Apathy in Neurodegenerative Disorders
Current main levels of evidence have been reported so far with cholinergic, glutamatergic and dopaminergic agents to reduce levels of apathy, despite several conflicting results.
Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management
Key areas for future research include the development of valid and reliable assessment tools for use in mechanistic studies and clinical trials, transdiagnostic studies of shared and distinct mechanisms and when and how to treat visual hallucinations.
Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues
Major issues related to NMF are summarized including clinical phenomenology and pathophysiology, and a number of open issues and topics for future research are outlined.
Challenges in Predicting Cognitive Decline in Dementia with Lewy Bodies
Assessment tools measuring cognitive domains predominantly affected in DLB need to be more consistently used in longitudinal studies and clinical practice, as well as concurrent measures of fluctuations in cognition, to enable more accurate monitoring and prediction of cognitive decline inDLB.


Clinical issues in the treatment of anxiety and depression in older adults with Parkinson's disease
It is suggested that cognitive behavior therapy is an effective approach to treatment of anxiety and depression in PD and should be offered as a treatment to patients.
Psychosocial Interventions for Depression and Anxiety in Parkinson's Disease
Cognitive behavioral therapy was the most studied and was shown to decrease depressive and anxiety symptoms in patients with PD and there is a need for additional studies on psychosocial interventions in people with PD.
Range of neuropsychiatric disturbances in patients with Parkinson’s disease
This study emphasises the importance of psychiatric symptoms in Parkinson’s disease, which were present in most patients and should be focused on the emotional and cognitive disturbances in addition to the motor manifestations of the disease.
Epidemiology of psychosis in Parkinson's disease
Disease-specific anxiety symptomatology in Parkinson's disease
Careful characterization of PD-specific anxiety symptomatology provides a basis for conceptualizing anxiety and assists with the development of a new PD- specific measure to accurately assess anxiety in PD.
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease
This interventional study provides Class II evidence that atomoxetine (target dosage = 80 mg/day) is not efficacious in improving clinically significant depression in PD, but was associated with improvement in global cognitive performance and daytime sleepiness.
Marked Improvement of Psychotic Symptoms After Electroconvulsive Therapy in Parkinson Disease
The results suggest a possible indication of acute ECT for refractory psychosis in patients with PD and suggest the effectiveness of electroconvulsive therapy for depression in PD but very few for psychosis.
The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease
Depression, apathy and sleep disturbance are more common in patients than in people without PD, and both psychological stress and brain changes associated with PD are likely to contribute to the higher frequencies.
The psychosis spectrum in Parkinson disease
This work discusses recent developments, including recognition of an increase in the prevalence of psychosis with disease duration, addition of new visual symptoms to the psychosis continuum, and identification of frontal executive, visual perceptual and memory dysfunction at different disease stages.